USP1 Program

TNG348 is a potent, selective, and allosteric inhibitor of USP1 (ubiquitin-specific protease 1) that is synthetic lethal with BRCA1 and BRCA2-mutations. BRCA1 or BRCA2 mutations are present in approximately 15% of ovarian cancers, 10% of breast cancers, 5% of prostate cancers, 5% of endometrial and 5% of pancreatic cancers.  A subset of lung and ovarian cancer cell lines without BRCA1 or BRCA2 mutations are also sensitive to USP1 inhibition, and work to understand this observation is ongoing.

  • In vivo preclinical studies of USP1 inhibition have shown single agent efficacy in BRCA1 and BRCA2-mutant cell-line and patient derived xenografts, including those that are intrinsically resistant to PARP inhibition. These preclinical data further demonstrate that TNG348 is synergistic with PARP inhibition across a panel of human ovarian and breast cancer cell lines, including both PARP inhibitor resistant and sensitive lines.
  • We are planning future clinical trials with TNG348 both as a single agent and in combination with PARP inhibitors.
  • The anti-cancer activity of USP1 inhibition extends to a panel of BRCA WT lung cancer cell line and xenograft models and we are evaluating potential patient selection biomarkers for this indication.
Learn more about our approach.Learn more about our approach.